<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Schwentke et al. BMC Microbiology 2012, 12:107 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br />  RESEARCH ARTICLE                                                                                                                                  Open Access <br />  <br /> In vitro vivo silencing plasmodial dhs <br /> and eIf-5a genes putative, non-canonical <br /> RNAi-related pathway <br /> Andreas Schwentke1, Marcel Krepstakies2, Ann-Kristin Mueller3, Christiane Hammerschmidt-Kamper3, <br /> Basma A Motaal2, Tina Bernhard1, Joachim Hauber2 Annette Kaiser1* <br />  <br />  <br />   <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br />   Background: Deoxyhypusine synthase (DHS) catalyzes step hypusine biosynthesis eukaryotic initiation <br />   factor 5A (eIF-5A) Plasmodium falciparum. Target evaluation parasitic DHS recently performed with <br />   CNI-1493, novel selective pro-inflammatory cytokine inhibitor used clinical phase II treatment of <br />   Crohn&apos;s disease. CNI-1493 prevented infected mice experimental cerebral malaria decreasing levels <br />   hypusinated eIF-5A serum TNF, implicating link cytokine signaling hypusine pathway. <br />   Therefore addressed question DHS itself eIF-5A required outcome severe <br />   malaria. In set experiments performed vitro knockdown plasmodial eIF-5A DHS <br />   proteins <span id='am-317' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-318' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-319' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-320' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-321' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-322' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-323' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-324' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-325' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-326' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-327' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-328' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-329' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-330' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-331' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-332' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-333' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-334' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-335' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-336' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-337' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-338' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-339' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-340' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-341' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-342' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-343' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-344' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-345' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-346' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-347' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-348' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-349' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-350' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-351' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-352' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-353' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-354' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-355' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-356' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-357' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-358' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-359' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-360' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-361' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-362' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-363' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-364' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-365' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-366' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-367' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-368' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-369' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-370' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-371' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-372' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-373' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-374' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-375' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-376' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-377' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-378' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-379' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-380' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-381' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-382' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-383' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-384' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-385' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-386' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-387' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-388' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-389' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-390' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-391' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-392' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-393' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-394' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span>RNA interference</span> (RNAi) 293 T cells. Secondly, transfection siRNA constructs murine <br />   Plasmodium schizonts performed which, turn, used infection. <br />   Results: 293 T cells treated plasmodial DHS- eIF-5A specific siRNAs control siRNAs analyzed by <br />   RT-PCR determine endogenous dhs -and eIF-5A mRNA levels. The expressed DHS-shRNA EIF-5A-shRNA <br />   clearly downregulated corresponding transcript cells. Interestingly, mice infected transgenic <br />   schizonts expressing eIF-5A dhs shRNA showed elevated parasitemia days post <br />   infection decreased intermittently. These results obtained drug selection. Blood samples, <br />   taken infected mice day 5 post infection expressed EIF-5A-shRNA the <br />   DHS-shRNA analyzed RT-PCR Western blot techniques, demonstrating absence the <br />   hypusinated form eIF-5A DHS. <br />   Conclusions: Infection NMRI mice schizonts lethal P. berghei ANKA wildtype strain transgenic for <br />   plasmodial eIF-5A-specific shRNA DHS-specific shRNA resulted low parasitemia 2&#226;&#8364;&#8220;9 days post infection before <br />   animals succumbed hyperparasitemia similar infections related non-lethal <span id='am-83' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-84' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-87' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-88' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-106' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-109' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-110' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-114' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-132' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-140' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-149' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-159' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-160' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span>phenotype</span> P. berghei <br />   strain NK65. RT-PCR Western blot experiments performed blood transfected erythrocytic stages <br />   showed genes important proliferation parasite. Moreover, experiments clearly <br />   demonstrate hypusine pathway Plasmodium linked human iNos induction. <br />  <br />  <br />  <br />  <br /> * Correspondence: annette.kaiser@uk-essen.de <br /> 1 <br />  University Duisburg-Essen, Medical Research Centre, Institute of <br /> Pharmacogenetics, Hufelandstrasse 55, 45147 Essen, Germany <br /> Full list author information available end article <br />  <br />                                            &#194;&#169; 2012 Schwentke et al.; licensee BioMed Central Ltd. This Open Access article distributed terms the <br />                                            Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), permits unrestricted use, <br />                                            distribution, reproduction medium, provided original work properly cited. <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                  Page 2 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br /> Background                                                    essential blood stages [9]. However, finding is <br /> RNA interference (RNAi) evolutionary conserved          question standard disruption techniques showed <br /> mechanism range eukaryotes,        effect parasitic development blood stages <br /> plays key role post-transcriptional gene regulation      [10]. While authors suggested RNAi be <br /> and protection genomes. The process RNAi trig-       functional Plasmodium, cases resulted <br /> gered recognition double-stranded RNA               parasitic death significant growth defects <span id='am-4' about='protege:TO' typeof='owl:Thing'>to</span> <br /> (dsRNA), processed 21&#226;&#8364;&#8220;25 nucleotide        unspecific downregulation multiple genes RNAi. <br /> sequences Dicer, cytoplasmic dsRNA specific RNa-            Deoxyhypusine synthase (DHS) catalyzes step <br /> seII endonuclease [1]. The generated RNAs associate           biosynthesis amino acid hypusine (Hyp), a <br /> with RNA-induced silencing complex (RISC) un-          novel amino acid present eukaryotic initiation factor <br /> wind strand-specific manner [2]. The resulting short     5A (eIF-5A) form deoxyhypusinylated intermedi- <br /> interfering RNAs (siRNAs) target homologous              ate. DHS transfers aminobutyl moiety tria- <br /> mRNA degradation combination RNase            spermidine &#209;&#8221;-amino group Lys50 present <br /> H enzyme Argonaute (Slicer) [3]. The stage double          hypusine loop. Both genes identified in <br /> stranded (ds) RNA processing surpassed experi-      P. falciparum P. vivax [11,12]. Hitherto, bio- <br /> mentally introducing sequence-specific siRNAs directly        logical function posttranslational modification is <br /> into cells.                                                   unknown. Recent studies implicated permissive <br />    Given immense Public Health costs malaria          role eIF-5AHyp various diseases. In diabetes type 2 <br /> disease need new drug targets silencing ap-     pancreatic stressed &#195;&#376;-cells [13] HIV-infected T <br /> proach employing RNAi extremely beneficial           cells, eIF-5AHyp functional nucleocytoplasmic <br /> for development novel advanced therapeutic         shuttle protein transport translation spe- <br /> strategies. Moreover, ability use RNAi gene        cific mRNAs [14]. <br /> silencing Plasmodium provide powerful means           Particularly HIV, eIF-5AHyp essential nucleo- <br /> to gain insight pathogenic blood stages.                 cytoplasmic transport translation incompletely- <br />    Recent experiments performed molecular genetics         spliced mRNAs encoding viral proteins [15,16]. In diabetes <br /> suggested RNAi functional malaria para-        type2 eIF-5AHyp enables cytokine-mediated islet dysfunc- <br /> sites [4]. These authors showed expression        tion direct posttranscriptional regulation of <br /> analyzed proteins continued despite application      mRNA encoding iNos2 (Nos2) rodent and <br /> variety RNAi-based strategies target genes        human cells [13,17]. Importantly, immunological <br /> are non-essential growth development          events lead severe malaria complex par- <br /> P. falciparum P. berghei. In good agreement, control       allel events present HIV-infection pancreatic <br /> experiments Trypanosoma brucei, protozoan para-        stressed &#195;&#376;-cells. Exogenous NO administration [18,19] <br /> site validated RNAi, successful. Furthermore,       prevents syndrome severe malaria. Since parasite <br /> to determine primitive RNAi machinery exists        specific nitric oxide synthase does exist, defense <br /> in Apicomplexa comparative analysis Apicomplexan         response attributed host specific iNos. <br /> and protozoan genomes undertaken. Taken to-            Cerebral malaria (CM) characterized clinical fea- <br /> gether data argued RNAi absent malaria       tures like cognitive dysfunctions, seizures, coma and <br /> parasites [4].                                                clinical parameters like anemia, metabolic acidosis, renal <br />    Several studies, however, reported successful appli-   insufficiency hypoglycaemia. Although under- <br /> cation RNAi gene silencing erythrocytic         standing malaria pathogenesis rudimentary, differ- <br /> stages Plasmodium. A series experiments        ent theories accepted understand the <br /> performed introducing long dsRNAs electropor-           pathological process [20]. The sequestration theory sug- <br /> ation infected erythrocytes. Gissot coworkers        gests seizures caused adherence of <br /> [5] performed silencing experiments MybB1, tran-       parasites red blood cells subsequent expression <br /> scription factor Plasmodium demonstrating          parasite specific antigens turn lead to <br /> its essential role erythrocytic stage. Kumar       obstruction blood flow, cerebral hypoxia decreased <br /> colleagues [6] showed similar manner requirement     removal waste. For neurological symptoms is <br /> of serine-threonine phosphatase DNA-replication      growing evidence parasite-induced sequestration of <br /> Plasmodium. Tuteja colleagues [7] identified signal     infected uninfected erythrocytes changes blood&#226;&#8364;&#8221; <br /> peptidase required intra-erythrocytic growth      brain barrier function. Moreover, host-specific immune <br /> by RNAi. Apart electroporation [8], siRNAs          mechanisms important response pres- <br /> also added directly culture medium. Cysteine      ence parasites CNS. <br /> proteases falcipain-1 falcipain-2, necessary       In step infection process parasitized red <br /> for haemoglobin degradation, shown            blood cells adhere brain microvascular endothelial <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                             Page 3 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br /> cells erythrocyte membrane protein [21].         contrast, control siRNA lacks complementary <br /> After release merozoites parasitic glycosylphosphati-     sequences human genome did negatively <br /> dylinositol (GPI) released induces local          affect abundance Plasmodium transcript with <br /> inflammatory response involving natural killer sub-      expected size 612 bp (amino acid positions 208&#226;&#8364;&#8220; <br /> sequently CD4+ T cells. At stage infection,      412) (lane 1). To exclude off-target effects number <br /> proinflammatory cytokines including tumor necrosis fac-      control experiments performed. As positive <br /> tor &#206;&#177; (TNF-&#206;&#177; interferon &#206;&#179; (IFN-&#206;&#179; interleukin (IL)-1&#195;&#376;     control recombinant plasmodial DHS expression <br /> are produced locally entry systemic        vector transfected 293T cells. Following <br /> phase cytokines activate macrophages            RT-PCR cDNA fragment 612 bp detected <br /> CD8+ T cells [21]. In systemic phase, platelets     (lane 3). No transcript observed untrans- <br /> and microparticles released inducing perforin-           fected 293Tcells analyzed (lane 2). Next, ampli- <br /> mediated lesions endothelium [21].                    fied human GAPDH sequence, representing a <br />   Recently, metabolic changes central nervous         housekeeping gene, control various cotransfec- <br /> system caused parasite, characterized       tions. As shown, presence expected GAPDH <br /> as theory explaining pathology malaria.    amplificate detected analyzed samples <br /> During CM increase lactate alanine concentra-      (Figure 1B), suggesting silencing effect the <br /> tion alterations tryptophane metabolites like     DHS siRNA used specific dhs amplificate <br /> kynurenine pathway lead increased permeability      does homology human orthologue. <br /> the blood brain barrier plasma proteins.                 In separate set experiments applied 4 different <br />   DHS recently validated druggable target      shRNAs knock eIF-5A precursor protein. <br /> by small molecule CNI-1493, synthetic guanylhy-        The pSilencer1.0-U6 vectors expressing different eIF-5A <br /> drazone [22], significantly extends <span id='am-5' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-6' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-35' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-67' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-69' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-80' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-82' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span>survival</span>       shRNAs (#5, #6, #7, #18; Materials Methods <br /> rate Plasmodium berghei ANKA-infected C57BL/6             (Additional file 1: Figure S1) individually <br /> mice [22]. Initial studies compound suggested       cotransfected plasmodial eIF-5A expression vector <br /> that mechanism action attributed in-    293T cells. Again, monitoring eIF-5A tran- <br /> hibition parasitic DHS translation host spe-   script abundance performed RT-PCR. <span id='am-2' about='protege:FROM' typeof='owl:Thing'>From</span> the <br /> cific TNF&#206;&#177;-mRNA [23], indicating link host         4 tested eIF-5A siRNAs shRNA #18 (Figure 2A, <br /> cell proinflammatory cytokine production hypu-       lane 3) capable completely downregulating the <br /> sine pathway.                                                plasmodial eIF-5A mRNA level 293T cells. For all <br />   To study outcome vivo knockdown            constructs vitro knockdown unsuccess- <br /> of enzyme target protein eIF-5A          ful (our data; shown). <br /> erythrocytic stages Plasmodium detail,               Control reactions non-transfected cells <br /> we transfected siRNA constructs targeted             (Figure 2A, lane 1) eIF-5A shRNA #18 cotransfected <br /> genes based vitro knockdown experiments           aquaporin-specific siRNA (Figure 2A, lane 4) <br /> P. berghei ANKA schizonts, using standard transfection       did change silencing effect. Although eIF-5A is <br /> methods [24].                                                highly conserved protein eukaryotes nucleic <br />                                                              acid sequence significantly divergent comparison <br /> Results                                                      human orthologue amplificates from <br /> In vitro knock-down P. falciparum DHS eIF-5A          endogenous eIF-5A expected. Again, moni- <br /> by RNAi                                                      tored presence GAPDH RT-PCR transfec- <br /> Two different DHS short hairpin RNAs (shRNAs), #43           tions (Figure 2B) independently presence the <br /> and #176 (see Materials Methods section), expressed      siRNA construct. <br /> from pSilencer1.0-U6 vector applied knock           To validate RT-PCR experiments limit <br /> down DHS protein P. falciparum. The shRNA           detection corresponding mRNAs i.e. eIF-5A <br /> #43 targets dhs sequence nucleotide positions         dhs determined. Titrated dhs-specific mRNA <br /> 337&#226;&#8364;&#8220;358, shRNA #176 targets dhs sequence        resulted limit detection 20 ng eIF-5A- <br /> nucleotide positions 1269&#226;&#8364;&#8220;1290 P. falciparum      specific mRNA detected concentra- <br /> mRNA. Both constructs individually cotransfected        tion 200 ng. Optimal primer binding determined <br /> with plasmodial DHS expression vector 293T cells        eIF-5A-specific primers cDNA concentration of <br /> to verify expected degradation dhs transcript.    130 ng dhs-specific primers cDNA concen- <br /> The results obtained RT-PCR analysis signifi-      tration 650 ng (data shown). <br /> cant knock-down plasmodial dhs transcript             In sum, data demonstrated Plasmodium- <br /> shRNA P #176 construct (Figure 1A, lane 4), opposed       specific eIF-5A DHS sequences principal be <br /> to shRNA P #43 expressed (lane 5). By           silenced RNAi. <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                                    Page 4 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br />  Figure 1 A) Inhibition plasmodial DHS RNAi monitoring 612 bp amplificate RT-PCR transfection 293 T <br />  cells DHS expression vector. 293T cells cotransfected with: 1) Scramble II-duplex shRNA; 2) transfected DNA; 3) the <br />  recombinant pcDNA3 vector containing 612 bp -highly conserved region dhs gene P. falciparum (amino acid positions 208&#226;&#8364;&#8220;412); <br />  4) DHS- shRNA construct P#176; 5) DHS- shRNA construct P#43. B) Analysis 983 bp GAPDH amplificate cotransfected 293T cells <br />  described Figure 1A. <br />  <br />  <br /> Monitoring vivo silencing eIF-5A DHS                        disappearance respective transcripts, least <br /> erythrocytic stages infection NMRI mice                    detection level assay. By contrast, the <br /> transgenic schizonts P. berghei                                     eIF-5A sequences clearly detected erythro- <br /> With regard vitro results, investigated                     cytic stage infection schizonts, were <br /> the silencing effect expressed DHS-specific                   transfected dhs-specific shRNA #176 vector <br /> eIF-5A specific shRNAs in vivo rodent model                        (Figure 3A, lane 1). Several control reactions were <br /> of P. berghei ANKA strain [24]. Infection NMRI                        applied. The RT-PCR reactions kanamycin control <br /> mice P. berghei ANKA wild type strain leads                      RNA 1.2 kb (Figure 3A, lane 5) the <br /> experimental cerebral malaria 6 10 days p. i.                  recombinant eIF-5A plasmid P. vivax moni- <br /> although parasitemia range 3&#226;&#8364;&#8220;5%                    tored, resulting amplification products approxi- <br /> infected erythrocytes. In case infectious non                 mately 323 bp 448 bp, respectively (Figure 3A, <br /> <span id='am-239' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-240' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-241' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-243' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-245' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-247' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-248' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-250' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-251' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-254' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-255' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-256' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-260' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-263' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-265' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-267' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-268' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-269' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-270' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-271' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-272' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-276' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-278' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-281' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-283' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-284' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-286' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-288' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-289' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-291' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-292' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-293' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-294' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-295' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-298' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-299' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-301' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-304' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-306' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-307' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-308' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-310' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-311' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-312' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-314' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-315' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-316' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span>lethal phenotype</span> P. berghei strain NK56, infected                    lanes 5 4). In parallel confirmed quality of <br /> mice succumb high parasitemia 80 days p.i.                     total cellular RNA preparation presence of <br /> without cerebral malaria.                                                &#206;&#177;-tubulin II sequences, expressed the <br />    In step DHS-specific shRNA #176 eIF-5A-                    asexual blood stages Plasmodium (lane 4). <br /> specific shRNA #18 expressed pSilencer 1.0-U6                         Next monitored effect vivo eIF-5A silen- <br /> vector transfected schizonts, late develop-                 cing protein level. As shown Figure 3B, eIF-5A <br /> mental stage parasite. These transgenic schizonts                 protein absent NMRI infected mice trans- <br /> were applied NMRI mice infection. In vivo gene                    genic schizonts expressing #18 eIF-5A-specific <br /> silencing monitored animals&#226;&#8364;&#8482; erythrocytes                     shRNA. In experiments polyclonal anti-eIF-5A <br /> at day 2 post infection RT-PCR before. Infection                   antibody raised highly conserved P. vivax <br /> with schizonts containing eIF-5A-specific shRNA                      protein (96% identity) used. NMRI mice infected <br /> #18 vector (Figure 3A lane 2) led complete                          transgenic schizonts expressing #176 DHS- <br />  <br />  <br />  <br />  <br />  Figure 2 A) Silencing parasitic EIF-5A RNAi 293 T cells subsequent monitoring RT-PCR. A cotransfection performed <br />  with: 1) transfected DNA; 2) recombinant, plasmodial eIF-5A expression plasmid 483 bp cDNA; 3) EIF-5A-shRNA construct P#18; <br />  4) aquaporin-5-specific siRNA. B) The 983 bp GAPDH amplificate used internal control transfected mammalian cell line. <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                                           Page 5 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br />  Figure 3 A) Monitoring vivo silencing parasitic eIF-5A RT-PCR RBCs infected NMRI mice 2 days post infection. NMRI <br />  mice infected transgenic schizonts harbouring expressed shRNA P#18. M1) 1 kb ladder (LifeTechnologies, Karlsruhe, Germany); <br />  1) non-transfected 293T cells 2) EIF-5A-siRNA; 3) A positive control quality cellular RNA 548 bp amplificate generated with <br />  &#206;&#177;-tubulin gene-specific primers P. berghei; 4) A PCR-control reaction eIF-5A-gene specific primers P.vivax generates 448 bp cDNA <br />  fragment; 5) Amplificate 323 bp obtained RT-PCR control reaction 1.4 kb kanamycin mRNA; M2) 100 bp ladder (Life Technologies, <br />  Karlsruhe, Germany). B) Western Blot analysis parasitic sh-eIF-5A expression transgenic schizonts infection NMRI mice. Protein <br />  extracts generated from: 1) shEIF-5A RNA #P18; 2) shDHS-RNA; #P176; 3) protein extract RBCs infected P. berghei ANKA strain and <br />  4) mock strain (without transfected shRNA); 5 6) different protein concentrations EIF-5A histidine-tagged, purified protein. 7) Standard <br />  protein marker (Roth). Polyclonal-antibody EIF-5A protein P. vivax applied concentration 1:1000 detected the <br />  protein band molecular weight 20 kDa. The protein concentrations extracts 10 &#206;&#188;g/&#206;&#188;l. C) Confirmation specificity of <br />  used anti-eIF-5A antibody Western Blot analysis. 1) Protein extract prepared NMRI infectected mice expressing #18 eIF-5A-specific <br />  shRNA, supplemented recombinant eIF-5A protein P.vivax; 2) purified, recombinant EIF-5A protein P.vivax; 3) Protein extract <br />  prepared NMRI infected mice expressing #18 eIF-5A-specific shRNA. The protein concentration 10 &#206;&#188;g lane. <br />  <br />  <br /> specific shRNA construct showed unmodified                          infected NMRI mice expressing #18 eIF-5A-specific <br /> or hypusinated eIF-5A protein present (Figure 3B,                        shRNA spiked purified eIF-5A protein from <br /> lane 2). This result implies #176 DHS-specific                      P. vivax (Figure 3C, lane 1). The P. vivax anti-eIF5A <br /> shRNA construct exclusively affects DHS protein.                         antibody clearly detected EIF-5A protein the <br /> Although eIF-5A modified abundant                       respective extract (lane 1) EIF-5A protein ab- <br /> in unhypusinated form, recognized poly-                     sent crude extract P. berghei ANKA strain <br /> clonal anti-eIF-5A antibody (Figure 3B, lane 2). The                         (Figure 3C, lane 3). Moreover, purified, recombinant <br /> results support observation RNA en-                     eIF-5A protein clearly recognized antibody <br /> coding eIF-5A gene present erythrocytic                        (Figure 3C, lane 2). These data suggest vivo <br /> stages infection schizonts expressing                         knockdown eIF-5A possible. <br /> DHS-shRNA #176 (Figure 3A, lane 4). The polyclonal                             A DHS-specific RT-PCR performed control <br /> antibody detected eIF-5A protein size                          formation 1248 bp cDNA fragment the <br /> 17,75 kDa P. berghei ANKA strain (Figure 3B, lane                     erythrocytic stages infection NMRI mice with <br /> 3) mock control strain (Figure 3B, lane                    transgenic schizonts harbouring DHS-shRNA #176 <br /> 4), eIF-5A protein P. vivax displayed                     eIF-5A #18 construct (Figure 4A, lanes 1&#226;&#8364;&#8220;2). A <br /> expected molecular mass approximately 20 kDa (lanes                       dhs-specific transcript detectable #176- <br /> 5 6).                                                                    infected (shRNA expressing) erythrocytes (lane 1), while <br />   To support specificity polyclonal                       present #18-infected (shRNA expressing) <br /> anti-EIF-5A antibody, protein extracts obtained                     erythrocytes (lane 2) control reaction with <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                                        Page 6 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br />  Figure 4 A) Monitoring vivo knockdown P. berghei infected schizonts transgenic expressed plasmodial DHS shRNA by <br />  RT-PCR days post infection NMRI mice. NMRI mice infected transgenic schizonts transfected plasmodial shRNA <br />  P#176 construct. M1) 1 kb ladder (LifeTechnologies, Karlsruhe, Germany); 1) DHS-shRNA; 2) EIF-5A-shRNA; 3) Amplification recombinant <br />  pcDNA3 vector carrying dhs gene P. falciparum generates cDNA fragment 1491 bp. 4) Quality control total, cellular RNA by <br />  amplification 548 bp fragment &#206;&#177;-tubulin gene-specific primers P. berghei; 5) PCR-control recombinant eIF-5A (448 bp) expression <br />  vector eIF-5A primers; M2) 100 bp ladder (LifeTechnologies, Karlsruhe, Germany) B) In vivo silencing plasmodial DHS monitored by <br />  Western blot analysis infection NMRI mice transgenic schizonts expressing shDHS. 1 2) Two different concentrations purified, <br />  human DHS protein; 3) PB ANKA wild type strain protein extract 4) Mock strain protein extract; 5) eIF-5A shRNA P#18; 6) DHS- shRNA P#176. C) <br />  Validation anti-DHS antibody specificity crude protein extracts prepared infection NMRI mice expressing plasmodial DHS #176 shRNA <br />  construct. M) Blueeye Marker; 1) crude protein extract infected NMRI mice plasmodial DHS #176 shRNA construct supplemented <br />  recombinant human protein; 2) crude protein extract infected NMRI mice plasmodial DHS #176 shRNA construct; 3) purified <br />  recombinant human DHS protein. The protein concentration 10 &#206;&#188;g lane. <br />  <br />  <br /> plasmodial dhs-specific primers (lane 3). Additionally,                    amino acid identity P. vivax orthologue 56% <br /> the quality cellular RNA confirmed P.                      identity P. berghei. These highly conserved amino acid <br /> berghei specific &#206;&#177;-tubulin primers (lane 4) reverse                     regions apparently recognized human anti- <br /> transcription using 1.2 kb Kanamycin-mRNA (lane 5).                      body. Protein extracts prepared infection with <br /> In parallel controlled vivo silencing DHS levels                  P. berghei (lane 3) mock strain (lane 4) showed <br /> by Western blot analysis (Figure 4B). A polyclonal anti-                   expected 49 kDa orthologue DHS. DHS was <br /> DHS antibody raised human DHS protein                          completely abundant eIF-5A-shRNA mutant #18 <br /> detected predicted size 41 kDa different                       (lane 5) faint band visible DHS-shRNA <br /> concentrations purified human DHS applied                          mutant (lane 6), cDNA detected in <br /> (lanes 1 2). Results amino acid alignment                      RT-PCR reaction. <br /> showed human DHS isoform1 shares 57% amino                               Again, performed eIF-5A, specifi- <br /> acid identity P. falciparum 3D 7 orthologue, 58%                    city human anti-DHS antibody confirmed. <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                      Page 7 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br /> Protein extracts prepared infected NMRI mice                Studies effect cytokines iNos production due <br /> harbouring expressed sh-RNA construct #176                  posttranslational modification eIF-5A <br /> supplemented recombinant, human DHS protein                     To investigate possible link cytokine signal- <br /> (Figure 4C, lane 1). The human anti-DHS antibody                     ing translation iNos2 mRNA host, <br /> clearly detected recombinant human protein (lane 3)              Western blots performed protein extracts <br /> and added DHS protein (lane 1). However,                  serum infected erythrocytic stages NMRI <br /> extract plasmodial shRNA #176 DHS signal                  mice. Figure 6 shows signals iNos2 absent <br /> was absent (lane 2). These data demonstrate validity             serum p. i. DHS silencing construct P #176 <br /> of antibody.                                                    eIF-5A-shRNA construct P #18 (Figure 6, lanes 1 <br />                                                                      2), iNos2 protein molecular size of <br /> Monitoring parasitemia infection schizonts                  approximately 131 kDa detectable P. berghei <br /> transfected eIF-5A- DHS-specific siRNA                      ANKA strain infected erythrocytes (Figure 6, lane 3). <br /> With respect vitro silencing data, P. berghei puri-        Most notably, prominent signals iNos2 protein were <br /> fied schizonts transfected eIF-5A               detected immortalized T cells (Jurkat cells) (Figure 6, <br /> shRNA construct (P #18) DHS shRNA (P #176) con-               lane 4 uninduced lane 5 induced) monocytic <br /> struct. In cases, transfected cells tracked in-        cell line (Mono Mac) (Figure 6, lane 6). No signal was <br /> fection recipient outbred NMRI mice                   obtained HeLa cells (lane 7). <br /> selection pressure.                                                     There difference signal intensity between <br />    In independent, different sets experiments                 induced uninduced cells probably induc- <br /> infection mice monitored transfection                tion ionomycin/PMA (phorbol 12-myristate 13- <br /> recombinant schizonts expressing P #176 DHS-              acetate), correct inductor to <br /> shRNA, P #18 construct (eIF-5A-shRNA) (Figure 5).             stimulate cytokine cell signaling. <br /> As control, infection performed using mock                   To support results nitric oxide quan- <br /> strain, transfected DNA. From day 2               tified colorimetric assay enzymatic conver- <br /> to day 10 post infection, parasitemia significantly              sion nitrate nitrite enzyme nitrate reductase <br /> lower lines compared untransformed mock               followed detection nitrite colored azo dye <br /> strain. By contrast, mock strain displayed parasitemia         product. The formed nitrite nitrate <br /> of 9% day 6 post infection, compared transfected           nitric oxide approximately 20-fold lower the <br /> parasites DHS-shRNA (4.5%) eIF-5A-                   serum infection mice shRNA construct <br /> shRNA. After 9 days post infection, parasitemia increased            P #18 (108,8 &#206;&#188;M/L) (Table 1) 18-fold lower the <br /> significantly infection experiments, harbouring ei-          shRNA construct P #176 (120 &#206;&#188;M/L) (Table 1) com- <br /> ther transgenic schizonts DHS-shRNA              parison wild type (2260,5 &#206;&#188;M/L). <br /> eIF-5A-shRNA. <br />                                                                      Discussion <br />                                                                      Hitherto, biological function unusual amino <br />                                                                      acid hypusine studied Plasmodium. Pre- <br />                                                                      vious studies showed hypusination eIF-5A im- <br />                                                                      portant cell proliferation parasite [11]. <br />                                                                      Deoxyhypusine synthase (DHS), catalyzes first <br />                                                                      step hypusine pathway recently targeted <br />                                                                      small molecule inhibitor, CNI-1493, blocked <br />                                                                      parasitic growth vitro vivo [22]. Another excel- <br />                                                                      lent way study biological function post- <br />                                                                      translational modification genetic <br />                                                                      analysis loss function proteins involved in <br />  Figure 5 Parasitemia outbred infected recipient mice post        hypusine biosynthesis. <br />  transfection schizonts transgenic parasitic eIF5A-           For future important issue pursue <br />  shRNA DHS-shRNA. Infection construct was <br />                                                                      targeted, stable gene disruption dhs eIF- <br />  performed different independent experiments mice <br />  condition. Pale blue triangles blue points represent    5Agenes Plasmodium, exact function in <br />  curves determined parasitemias post infection      erythrocytic life cycle stages unknown. To <br />  shDHS P#176 mice. Pale blue upside triangles blue   date gene disruption insertion strategy suc- <br />  squares represent monitored parasitemia expressed      cessfully shown rodent model P. berghei and <br />  eIF5A-sh P#18. The parasitemia mock control strain is <br />                                                                      partly working intraerythrocytic schizogeny <br />  represented pale blue dot pale blue rhomb. <br />                                                                      P. falciparum [24,25]. <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                                         Page 8 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br />   Figure 6 Cytokine signaling human iNos2 translation dependent hypusine pathway infection Plasmodium. <br />   Western Blot analysis performed equal amounts protein (10 &#206;&#188;g) extracted infected erythrocytic stages transgenic <br />   schizonts P. berghei ANKA strain 1) protein extract prepared serum infection schizonts harbouring expressed plasmodial <br />   DHS-shRNA 2) eIF-5A-siRNA expression construct; 3) P. berghei ANKA strain; 4) induced 5) non- induced Jurkat cells; 6) Mono Mac 1 <br />   cells; 7) HeLa cells; M) Standard protein marker Roth, St. Leon, Germany. Detection iNos2 protein molecular size 131 kDa was <br />   performed human anti-Nos2 antibody dilution 1:1000. <br />  <br />  <br />   The understanding cerebral malaria (CM) patho-                          performed showing 50% reduction expression <br /> genesis rudimentary [26]. Our results clearly dem-                  level berghepains homologues cysteine <br /> onstrate hypusine pathway Plasmodium                             proteases Plasmodium [27]. For siRNA experi- <br /> supports different hypotheses patho-                     ments, strategy reduce gene expression cultured <br /> genesis cerebral malaria i.e. sequestration theory                    cell lines pSilencer1.0-U6 vectors producing the <br /> and inflammation hypothesis. One underlying                       respective shRNAs U6 promotor selected. <br /> mechanisms cerebral malaria pathogenesis                             The data indicate vitro knockdown eIF- <br /> adherence parasitized red blood cells vascular                         5A different shRNAs completely ablat- <br /> endothelial cells parasite specific proteins. Infected                    ing eIF-5A expression shRNA # P18 in <br /> NMRI mice transfected schizonts transgenic                          293 T cells (Figure 2A, lane 3) markedly reduced <br /> plasmodial eIF-5A- DHS-specific shRNA showed                            eIF-5A transcript level. These shRNA con- <br /> 50% reduced parasitemia comparison untrans-                        structs eIF-5A targeted eIF-5A <br /> fected control 2 9 days post infection. This                       sequence. The eIF-5AshRNA #18, targets posi- <br /> may indicate preventing parasitic sequestration.                      tions 163&#226;&#8364;&#8220;184 eIF-5A nucleic acid sequence, <br />   In approach test possibility                      caused complete decrease eIF-5A mRNA levels. <br /> knockdown DHS precursor protein eIF-5A                         These results agreement structural model <br /> possible Plasmodium, vitro knockdown RNAi                        human eIF-5A1 [30], consists domains, <br /> was performed unequivocal demonstration                        basic N-terminal domain hypusine loop and <br /> the Plasmodium genome contains conserved                          acidic -terminal domain connected hinge. <br /> RNAi machinery genes enzymes date missing.                          Within basic N-terminus, hypusine modification <br /> In past, RNAi circulating malaria parasites                       covers amino acid positions 46&#226;&#8364;&#8220;54 i. e. nucleic acid posi- <br />                                                                              tions 138&#226;&#8364;&#8220;162 close 3&#226;&#8364;&#8482; prime end <br /> Table 1 Colorimetric determination nitric oxide                           hypusine loop. <br /> formation nitrate nitrite sera infected                         By contrast eIF-5A shRNA #7 targets position 115&#226;&#8364;&#8220; <br /> mice obtained P.berghei ANKA strain infection                      136, proximal 5&#226;&#8364;&#8482;-end loop, does <br /> after infection schizonts harbouring expressed                      affect mRNA abundance. It likely second- <br /> plasmodial DHS shRNA #176 plasmodial EIF-5A                               ary structure hypusine loop position might <br /> shRNA #18                                                                    block degradation specific mRNA [28]. Taken <br /> Nitrate nitrite [&#206;&#188;mol/L]                   Wild type transfectants   together, tested shRNAs, one, eIF- <br /> 2200,5                                         P. berghei ANKA wild type     5A-specific shRNA #18 caused considerable decrease <br /> 120                                            DHS-specific shRNA # 176      eIF-5A transcript vitro. <br /> 109                                            EIF-5A-specific shRNA # 18      Two DHS-shRNAs, #43 #176, targeting nucleotide <br /> Nitrate nitrite determination infection mice transgenic <br />                                                                              positions 337&#226;&#8364;&#8220;358 bp 1269&#226;&#8364;&#8220;1290 bp, respect- <br /> schizonts expressing plasmodial DHS EIF-5A shRNAs.                       ively, employed vitro knockdown DHS <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                   Page 9 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br /> from Plasmodium. Surprisingly, DHS-shRNA con-               shRNA mutants P #176 (DHS) P #18 (EIF5A) a <br /> struct #176 successful downregulate dhs tran-        18-fold 20-fold lowered formation nitric oxide. <br /> script significantly (Figure 1A, lane 5),          These findings prove link the <br /> targeted sequence did cover active site          hypusine pathway iNos production broaden <br /> enzyme amino acid region Lys287              understanding CM malaria pathology and <br /> and Glu323 [28,29].                                             implicate alternative strategies therapy. Similar results <br />    Subsequently, monitoring vivo silenced P. berghei      obtained DHS heterozygous <span id='am-161' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-162' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-164' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-179' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-181' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-190' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-192' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-198' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-201' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-207' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-208' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-210' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-212' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-218' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-223' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-224' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-227' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-230' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-231' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-235' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-237' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-238' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span>knockout</span> <br /> blood stage parasites transgenic eIF-5A-             mice attenuated cytokine signalling evidenced by <br /> shRNA DHS-shRNA post transfection performed              reduced nitric oxide synthase production [31]. <br /> by RT-PCR. In case eIF-5A-shRNA containing                  Malaria patients present hypoargininemia <br /> blood stages eIF-5A transcript present              [32], metabolomic studies Plasmodium falcip- <br /> (Figure 3A, lane 2), erythrocytes DHS-        arum 48 h intraerythrocytic life cycle reveal <br /> shRNA (Figure 3A, lane 2) dhs cDNA abun-            nearly complete depletion L-arginine levels. Nitric <br /> dant (Figure 4A, lane 1). However, eIF-5A transcript        oxide synthase induced arginine catalyzes the <br /> was detectable, suggesting silencing effect         reaction nitric oxide (NO) urea. However, cere- <br /> rather specific.                                                bral malaria lack nitric oxide the <br />    Moreover, results confirmed Western            presence parasite-specific arginase leads a <br /> blot analysis 17,75 kDa eIF-5A protein            depletion arginine subsequent downregulation of <br /> absent transgenic P. berghei ANKA parasites har-         host-specific nitric oxide synthase. This allow the <br /> bouring eIF-5A-specific siRNA. Both proteins, i.e.          parasite evade NO-dependent immune response in <br /> the P. falciparum P. berghei homolog share              host NO deleterious parasite proliferation <br /> amino acid identities 73%. In control experiment           [33]. During Plasmodium berghei ANKA infection in <br /> the antibody raised eIF-5A protein             mice exogenous nitric oxide decreases brain vascular <br /> P. vivax crossreacted eIF-5A homologue            inflammation, leakage venular resistance [17,18] and <br /> the mock strain P. berghei ANKA strain result-          protects cerebral malaria. <br /> ing protein 17,75 kDa [30] (Figure 3B, lanes 3             Finally, crystal structure Plasmodium arginase <br /> and 4). To monitor suppressed DHS expression poly-            resolved recently indicates low complex- <br /> clonal human antibody applied detected                ity region [33] largely disordered dele- <br /> the P. berghei orthologue 49 kDa (Figure 4B, lanes 3         tion does significantly compromise enzyme activity. <br /> and 4) mock control P. berghei ANKA              Moreover, disruption P. falciparum arginase led an <br /> strain. By contrast faint band detected DHS        apparent reduction liver stage infection. <br /> siRNA mutant suggesting gene be <br /> silenced completely.                                            Conclusions <br />    The inflammation hypothesis cerebral malaria im-          Although previously suggested RNAi is <br /> plies brain damage result inflammatory         functional Plasmodium, putative, non-canonical <br /> response human host parasite central       RNAi pathway exist malaria parasites. In vivo <br /> nervous (CNS). The production proinflamma-            knockdown eIF-5A DHS expression shRNAs <br /> tory cytokines like IL-1&#206;&#178;, TNF-&#206;&#177;, IFN-&#206;&#179; leads secre-         infection rodent model decreased parasitemia <br /> tion nitric oxide kills parasite. It      intermittently development cerebral malaria. <br /> recently reported hypusinated eIF-5A required        The data similar related non-lethal pheno- <br /> part nuclear export translation iNos-            type P. berghei ANKA NK 65. These results of <br /> encoding mRNAs pancreatic, stressed &#195;&#376;-cells            study function hypusine modifi- <br /> release proinflammatory cytokines [17]. To test         cation respect malaria infection therapy. <br /> hypothesis host iNos2 protein levels monitored <br /> in serum infection P. berghei ANKA strain        Materials methods <br /> the transfected shRNAs P #176 (DHS) P #18               Ethics statement <br /> (EIF5A), parasitic nitric oxide synthase absent.     All animal experiments performed FELASA <br /> We clearly demonstrate mutants               category B GV-SOLAS standards. Animal experi- <br /> there response cellular stress i.e. induction in-   ments approved German authorities (Regierung- <br /> ducible nitric oxide synthase (iNos2) human host         spr&#195;&#164;sidium Karlsruhe, Germany). <br /> once modification eIF-5A interrupted silencing <br /> of parasitic DHS eIF-5A. However, nitric oxide        siRNAs (small interfering RNAs) targeting DHS eIF-5A <br /> synthase induced 20-fold infection wild       The following double stranded siRNAs used and <br /> type P. berghei ANKA strain comparison                synthesized Ambion, Karlsruhe, Germany: RNAi for <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                             Page 10 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br /> DHS EIF5A knockdowns, siRNA duplexes               Cloning <span id='am-3' about='xsp:length' typeof='owl:Thing'>length</span> dhs cDNA eIF-5A cDNA into <br /> used obtained annealing RNA               eukaryotic pcDNA3 vector <br /> oligonucleotides synthesized Ambion, Karlsruhe,          Amplification dhs gene performed the <br /> Germany. The oligonucleotides (3000 mM dhs,             recombinant pet-Blue1 plasmid (Novagen, Darmstadt, <br /> 1500 mM eIF-5A) phosphorylated reaction       Germany) Plasmodium falciparum primers <br /> volume 20 &#206;&#188;l 3 Units polynucleotide kinase          containing recognition sites EcoRI (restriction site <br /> (10 U/&#206;&#188;l) (Roche Diagnostics, Penzberg, Gemany)          underlined) dhs forward 5&#226;&#8364;&#8482;-TTTGAATTCATGGTG <br /> 37&#194;&#176;C 45 min. The reaction stopped ice        GATCACGTTTC-&#226;&#8364;&#8482;3&#226;&#8364;&#8482; NotI dhs reverse 5&#226;&#8364;&#8482;- TTT <br /> 1 min. An annealing reaction performed 95&#194;&#176;C          GCGGCCGCTCACATATCTTTTTTCCTC- 3&#226;&#8364;&#8482;. The result- <br /> with subsequent cooling reaction room             ing fragment 1491 bp digested EcoRI and <br /> temperature overnight.                                      NotI ligated EcoRI/NotI treated pcDNA3 vector <br />   After annealing siRNA duplexes cloned       (Invitrogen, Darmstadt, Germany) re-sequenced. For <br /> pSilencer 1.0-U6 vector transfection 293T       construction eIF-5A cDNA containing pcDNA3 <br /> cells schizonts.                                         vector, eIF-5A nucleic acid sequence amplified <br />   For DHS knockdown #43, RNA oligonucleotides           recombinant plasmid pSTBlue-1 Acceptor&#226;&#8222;&#162; vector <br /> 5&#226;&#8364;&#8482;- UGUUAGUGAAGAUCUUAAUtt-3&#226;&#8364;&#8482; 5&#226;&#8364;&#8482;-AUUAA                   (Novagen, Darmstadt, Germany) primers containing <br /> GAUCUUCACUAACAtt-3&#226;&#8364;&#8482; applied targeting              EcoRI eIF-5Aforward 5&#226;&#8364;&#8482; -AAA GAA TTC ATG TCA <br /> nucleotide positions 337&#226;&#8364;&#8220;358 plasmodial dhs          GAC CAC GAA AC-3&#226;&#8364;&#8482; NotI eIF-5Areverse 5&#226;&#8364;&#8482;-TTT <br /> cDNA. For DHS knockdown #176, RNA oligo-                GCG GCC GCC TAG GAG GAC AAC TCC-3&#226;&#8364;&#8482; restric- <br /> nucleotides 5&#226;&#8364;&#8482;- UGAGGAAUGGUGCUGAUUUtt-3&#226;&#8364;&#8482;                tion sites. <br /> 5&#226;&#8364;&#8482;-AAAUCAGCACCAUUCCUCAtt-3&#226;&#8364;&#8482; applied which <br /> targeted nucleotide positions 1269&#226;&#8364;&#8220;1290 dhs cDNA.    Cotransfection pSilencer1.0-U6 vectors 293 T cells <br />   For eIF-5A knockdowns 4 different siRNA               In 6 microtiter plate 7x105 293T cells seeded <br /> duplexes generated. For EIF-5A knockdown           6 wells. Four different sets cotransfections were <br /> #5, RNA oligonucleotides 5&#226;&#8364;&#8482;- ACGGCCACGUGAUG                 performed: DHS; i) P. falciparum dhs cDNA pcDNA3 <br /> CUAAAtt-3&#226;&#8364;&#8482; 5&#226;&#8364;&#8482;- UUUAGCAUCACGUGGCCGUtt-3&#226;&#8364;&#8482;                 (0.3 &#206;&#188;g), ii) P. falciparum dhs cDNA pcDNA3 and <br /> were applied targeting nucleotide positions 81&#226;&#8364;&#8220;102   premade scramble II duplex negative control siRNA <br /> P. vivax eIF-5A cDNA. For EIF-5A knockdown #6,          (1.0 &#206;&#188;g), iii) P. falciparum dhs cDNA pcDNA3 and <br /> RNA oligonucleotides 5&#226;&#8364;&#8482;- AGGAGCAUCCUUGCAAA                  DHS- specific shRNA construct #43 (1.0 &#206;&#188;g), iv) P. fal- <br /> GUtt-3&#226;&#8364;&#8482; 5&#226;&#8364;&#8482;- ACUUUGCAAGGAUGCUCCUtt-3&#226;&#8364;&#8482;               ciparum dhs cDNA pcDNA3 DHS-specific <br /> applied targeted nucleotide positions 99&#226;&#8364;&#8220;120;     shRNA construct #176 (1.0 &#206;&#188;g). The various transfec- <br /> EIF-5A knockdown #7, RNA oligonucleotides 5&#226;&#8364;&#8482;-AGUG           tions mixed transfection mix (total vol. <br /> GUAGAUUACUCCACGtt-3&#226;&#8364;&#8482; 5&#226;&#8364;&#8482;- CGUGGAGUAAU                    400 &#206;&#188;l), contained Opti-MEMW (Invitrogen, <br /> CUACCACUtt-3&#226;&#8364;&#8482; used targeting nucleotide            Karlsruhe, Germany) polyethylenimine (PEI) (4 &#206;&#188;l/ <br /> positions 115&#226;&#8364;&#8220;136. For eIF-5A knockdown #18, RNA oli-       &#206;&#188;g), added cultures. After 10 min of <br /> gonucleotides 5&#226;&#8364;&#8482;- CUGAGUUGCAGCUGAUUGAtt-3&#226;&#8364;&#8482;                  incubation room temperature, culture superna- <br /> and 3&#226;&#8364;&#8482;- UCAAUCAGCUGCAACUCAGtt-5&#226;&#8364;&#8482; applied               tants substituted 2 ml DMEM (Dulbecco&apos;s <br /> which targeted eIF-5A gene nucleotide positions      Modified Eagle&apos;s Medium) (Invitrogen, Karlsruhe, Ger- <br /> 163&#226;&#8364;&#8220;184.                                                    many) cell cultures incubated overnight at <br />                                                             37&#194;&#176;C. The day, medium changed supple- <br />                                                             mented streptomycin (60 &#206;&#188;g/ml). Prior transfec- <br /> Construction pSilencer1.0-U6 vector double          tion, cells washed PBS-buffer (phosphate <br /> stranded siRNA DHS eIF-5A                            buffer saline). <br /> 20 &#206;&#188;g (Ambion/Invitrogen, Karlsruhe, Germany)          Cotransfection P. falciparum eIF-5A pcDNA3- <br /> double digested EcoRI/ApaI (20 U) reaction        based expression vector combination 4 different <br /> volume 20 &#206;&#188;l dephosphorylated calf intestine    sets siRNA vectors performed according a <br /> alkaline phosphatase (CIP) (MBI Fermentas, St. Leon         protocol Invitrogen (Karlsruhe, Germany): i) P. fal- <br /> Rot, Germany) (1 U/&#206;&#188;l) 1 hour 37&#194;&#176;C. The double       ciparum eIF-5A expression vector (0.3 &#206;&#188;g) and <br /> digested vector gel-purified according Mini      aquaporin-5 specific-siRNA (2.7 &#206;&#188;g) ii) P. falciparum <br /> Elute Gel Extraction Kit protocol Qiagen, (Hilden,     eIF-5A expression vector (0.3 &#206;&#188;g) eIF-5A-specific <br /> Germany). Ligation annealed oligos per-          shRNA construct #18 (2.7 &#206;&#188;g), iii) P. falciparum eIF5A <br /> formed ligation kit Roche Diagnostics,        expression vector (0.3 &#206;&#188;g) eIF-5A-specific shRNA <br /> (Penzberg, Germany). Positive constructs analysed      #6 (2.7 &#206;&#188;g), iv) P. falciparum eIF-5A expression vector <br /> after double digestion ApaI HindIII.               (0.3 &#206;&#188;g) eIF-5A shRNA construct #7 (2.7 &#206;&#188;g), v) <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                               Page 11 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br /> P. falciparum eIF-5A expression vector (0.3 &#206;&#188;g) eIF-      applied blood anticoagulant accord- <br /> 5A shRNA #5 (2.7 &#206;&#188;g).                                         ing protocol Proimmune [35]. <br />  <br /> Isolation cellular RNA                                     Western blot analysis <br /> Isolation total cellular RNA performed according       Western blots performed using i-Blot dry blot- <br /> to RNeasy Plant Mini Kit (Qiagen, Hilden, Germany).       ting device Invitrogen (Karlsruhe, Germany) <br /> The quality isolated RNA verfied agarose        5 min 5.5 amp 25 V. Protein extracts from <br /> gel electrophoresis quantity purity           blood stages transfected parasites resuspended in <br /> determined UV spectrometry.                                1-fold Nupage buffer (Invitrogen, Karlsruhe, Germany) <br />                                                               boiled loaded 12% SDS-polyacrylamide gel. <br /> RT-PCR analysis eIF-5A DHS silencing vitro      Immunodetection performed according proto- <br /> in vivo                                                       col immunodetection kit Amersham <br /> To monitor silencing eIF-5A DHS, RT-PCR            (Munich, Germany). Polyclonal anti-eIF5A antibodies <br /> was performed according protocol Access-        (Eurogentec, Cologne, Germany) raised the <br /> Quick&#226;&#8222;&#162; RT-PCR System (Promega, Mannheim, Ger-                 eIF-5A P. vivax anti-DHS antibodies against <br /> many). For RT-PCR reaction gene specific primers          P. falciparum DHS applied dilutions 1:1000 <br /> for eIF-5Aforward 5&#226;&#8364;&#8482;-ATGTCAGACCACGAAACGT-3&#226;&#8364;&#8482;/                  1:5000, respectively. Previous results shown that <br /> eIF-5A reverse 5&#226;&#8364;&#8482;-CTAGGAGGACAACTCCTTCACC                      human DHS protein cross-reacts P. berghei <br /> GC- 3&#226;&#8364;&#8482; dhs forward 5&#226;&#8364;&#8482;-ATAGTGCCTAATGA                      DHS protein highly conserved regions an <br /> TAATTA -3&#226;&#8364;&#8482;/dhs reverse 5&#226;&#8364;&#8482;-AACCTCCTCCGAGAA                     overall amino acid identity 56% (see results <br /> TAATAATACCAG -3&#226;&#8364;&#8482; used. For control, human                section) [11]. Dilutions 1:1000 1:5000 the <br /> GAPDH-specific sequences amplified using             antibody raised eIF-5A P. vivax were <br /> following primers: GAPDH forward 5&#226;&#8364;&#8482;-ATGGGGAAG                 used, proteins i.e. eIF-5A P. vivax and <br /> GTGAAGGTCGG-3&#226;&#8364;&#8482; GAPDH reverse 5&#226;&#8364;&#8482;-TTACTC                    P. berghei, share 97% amino acid identity [11]. <br /> CTTGGAGGCCATGTGG-3&#226;&#8364;&#8482;. For RT-PCR reactions <br /> monitoring cDNA formation in vivo experiments              Induction HeLa, jurkat monomac cells and <br /> after P.berghei infection following P. berghei-specific   preparation protein extracts <br /> PCR primers used: eIF-5A forward 5&#226;&#8364;&#8482;-ATGTCA               HeLa, Jurkat Monomac maintained Dulbec- <br /> GACCACGAAACGT-3&#226;&#8364;&#8482;/eIF5A reverse 5&#226;&#8364;&#8482;- TATGATGA                   co&#226;&#8364;&#8482;s modified Eagle medium (DMEM) (Sigma Aldrich, <br /> CATTTCTTTAAGC-3&#226;&#8364;&#8482; dhs forward 5&#226;&#8364;&#8482;-ATGGAT                    Munich, Germany), supplemented 10% (v/v) fetal <br /> GGGGTATTCAAAGA-3&#226;&#8364;&#8482;/dhs reverse 5&#226;&#8364;&#8482;-CTAATCACT                    bovine serum (FBS), L-glutamine (2 mM), sodium pyru- <br /> TTTTTCTCCTTTT-3&#226;&#8364;&#8482;. To analyze quality               vate (1 mM) penicillin (50000 U/ml) streptomycin <br /> cellular total RNA &#206;&#177;-tubulin forward 5&#226;&#8364;&#8482;-ATGAGA              (5 mg/ml)). <br /> GAAGTAATAAGTAT-3&#226;&#8364;&#8482; &#206;&#177;-tubulin reverse 5&#226;&#8364;&#8482;-TGT                  For stress induction HeLa, Jurkat Monomac cells <br /> TGATAAAACTGAATTAT-3&#226;&#8364;&#8482; primers applied,                    grown overnight cultures starving condi- <br /> resulting specific &#206;&#177;-tubulin fragment 548 bp.         tions (i.e. 1% FCS-containing medium). Thereafter, cul- <br />                                                               ture supernatants substituted DMEM <br /> Plasmodium transfection using shRNA expressing vectors        containing 10% FCS cells incubated for <br /> Parasite transfection using sh expression vectors     3 hours. Finally, cell cultures exposed 4 hours <br /> Pyrimethamine selection performed described            50 ng/mL phorbol 12-myristate 13-acetate (PMA) <br /> in [24].                                                      1 &#206;&#188;M calcium ionophore ionomycin. Subse- <br />                                                               quently, respective cell cultures washed several <br /> Preparation protein extracts transfected              times PBS. <br /> P. berghei parasites                                            In total 106-107 cells lysed CelLytic M solu- <br /> To detect eIF-5A DHS expression transfected            tion (Sigma Aldrich, Munich, Germany) 15 minutes <br /> and wildtype P. berghei parasites, intraerythrocytic stages   rocker platform. The lysed cells centrifuged at <br /> were purified CF11 Cellulose (Whatman) (Millipore,         12,000-20,000 x g pellet cellular debris. The <br /> Schwalbach, Germany) remove platelets leuko-           supernatant, containing cell lysate, used fur- <br /> cytes. Parasites lysed 0.2% saponin resus-        ther analysis. <br /> pended PBS (LifeTechnologies/Invitrogen, Karlsruhe, <br /> (Germany). After determination protein concen-         Determination total nitric oxide <br /> tration Bradford assay [34], extracts adjusted     Concentrations nitric oxide determined col- <br /> the protein concentration (20 &#206;&#188;g) PBS. Alter-       orimetric detection according kit protocol from <br /> natively, detection iNos protein, serum        Enzo Life Sciences. Nitric oxide converted nitrate <br />  Schwentke et al. BMC Microbiology 2012, 12:107                                                                                                         Page 12 13 <br /> http://www.biomedcentral.com/1471-2180/12/107 <br />  <br />  <br />  <br />  <br /> which reduced nitrite enzyme nitrate reduc-                            9.    Dasaradhi PV, Mohammed A, Kumar A, Hossain MJ, Bhatnagar RK, Chauhan <br /> tase followed colorimetric detection nitrite                               VS, Malhotra P: A role falcipain-2, principle cysteine proteases of <br />                                                                                           Plasmodium falciparum merozoite egression. Biochem Biophys Res <br /> coloured azo dye product absorbs visible light                                   Commun 2005, 336:1062&#226;&#8364;&#8220;1068. <br /> 560 nm. The determination allows determination                               10.   Sijwali PS, Rosenthal PJ: Gene disruption confirms critical role the <br /> both nitric oxide products nitrate nitrite.                                           cysteine protease falcipain-2 haemoglobin hydrolysis Plasmodium <br />                                                                                           falciparum. Proc. Natl. Acad. Sci. USA 2004, 101:4384&#226;&#8364;&#8220;4389. <br />                                                                                     11.   Kaiser A, Gottwald A, Maier W, Seitz HM: Targeting enzymes involved in <br /> Additional file                                                                           spermidine metabolism parasitic protozoa-a possible new strategy for <br />                                                                                           anti-parasitic treatment. Parasitol Res 2003, 91(6):508&#226;&#8364;&#8220;516. <br />                                                                                     12.   Njuguna JT, Nassar M, Hoerauf A, Kaiser AE: Cloning, expression and <br />  Additional file 1: Figure S1. Unsuccessful silencing parasitic <br />                                                                                           functional activity deoxyhypusine synthase Plasmodium vivax. <br />  EIF-5A RNAi 293T cells subsequent monitoring RT-PCR. <br />                                                                                           BMC Microbiol 2006, 6:91&#226;&#8364;&#8220;96. 16. <br />  A cotransfection performed with: lane 1) EIF-5A-shRNA construct P# <br />                                                                                     13.   Maier B, Ogihara T, Trace AP, Tersey SA, Robbins RD, Chakrabarti SK, <br />  5; lane 2) EIF-5A-shRNA construct P#; lane 3) EIF-5A-shRNA construct P# 7; <br />                                                                                           Nunemaker CS, Stull ND, Taylor CA, Thompson JE, Dondero RS, Lewis EC, <br />  lane 4) pcDNA3 based plasmodal EIF-5A expression vector; lane 5) P. <br />                                                                                           Dinarello CA, Nadler JL, Mirmira RG: The unique hypusine modification of <br />  falciparum eIF-5A expression vector aquarin-5 specific siRNA; lane 6) <br />                                                                                           eIF5A promotes islet beta cell inflammation dysfunction mice. <br />  EIF-5A-shRNA construct P# 18. <br />                                                                                           J Clin Invest 2011, 20(6):2156&#226;&#8364;&#8220;2170. <br />                                                                                     14.   Hauber I, Bevec D, Heukeshoven J, Kr&#195;&#164;tzer F, Horn F, Choidas A, Harrer T, <br /> Competing interests                                                                       Hauber J: Identification cellular deoxyhypusine synthase novel <br /> The authors declare competing interests.                                target antiretroviral therapy. J Clin Invest 2005, 115(1):76&#226;&#8364;&#8220;85. <br />                                                                                     15.   Bevec D, Kappel B, Jaksche H, Csonga R, Hauber J, Klier H, Steinkasserer A: <br /> Authors&#226;&#8364;&#8482; contributions                                                                    Molecular characterization cDNA encoding functional human <br /> MK involved transfection experiments, AS responsible               deoxyhypusine synthase chromosomal mapping the <br /> RT-PCR Western Blot experiments. AKM CHS performed P.                         corresponding gene locus. FEBS Lett 1996, 378(2):195&#226;&#8364;&#8220;198. <br /> berghei transfection. BAM TB involved cloning siRNA              16.   Hofmann W, Reichart B, Ewald A, M&#195;&#188;ller E, Schmitt I, Stauber RH, Lottspeich <br /> oligonucleotides. AK participated practically colorimetric assays              F, Jockusch BM, Scheer U, Hauber J, Dabauvalle MC: Cofactor requirements <br /> Western Blot experiments, prepared manuscript organized financial                 nuclear export Rev response element (RRE)- constitutive <br /> support, AKM JH critically appraised manuscript. We thank Barbara                 transport element (CTE)-containing retroviral RNAs. An unexpected role <br /> Langer excellent technical assistance. All authors read approved              actin. J Cell Biol. 2001, 152(5):895&#226;&#8364;&#8220;910. <br /> final manuscript.                                                                   17.   Maier B, Tersey SA, Mirmira RG: Hypusine: new target therapeutic <br />                                                                                           intervention diabetic inflammation. Discov. Med. 2010, 10(50):18&#226;&#8364;&#8220;23. <br /> Acknowledgements                                                                    18.   Zanni GM, Cabrales P, Barkho W, Frangos J, Carvalho L: Exogenous nitric <br /> The work supported main parts grant German                           oxide decreases brain vascular inflammation, leakage venular <br /> Academic Exchange Service (DAAD) AK (432/lz (2006).                                    resistance Plasmodium berghei ANKA infection mice. <br />                                                                                           J Neuroinflamm. 2011, 66(Zanni GM, Cabrales P, Barkho W, Frangos J, <br /> Author details                                                                            Carvalho L):1&#226;&#8364;&#8220;9. 8. <br /> 1 <br />  University Duisburg-Essen, Medical Research Centre, Institute                   19.   Hawkes M, Opoka R, Namasopo S, Miller C, Thorpe KE, Lavery JV, Conroy AL, <br /> Pharmacogenetics, Hufelandstrasse 55, 45147 Essen, Germany. 2Heinrich                     Liles WC, J <br /> </body></html>